Real-world Evidence on Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)
The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI
Real-world evidence on patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) long-term survival after treatment with liposomal irinotecan - NALLONG
Effectiveness and Impact on Quality of Life of a Combination of Trimetazidine With One Hemodynamic Agent (ß-blocker or Ca-channel Blocker), in Patients Recently Diagnosed With Stable Angina and Still Symptomatic Despite First Line Hemodynamic Therapy: a Prospective, International, Non-interventional Study.
The purpose of this study is to assess in recently diagnosed stable Angina patients symptomatic despite first line hemodynamic therapy, the effect of a combination of this hemodynamic agent with a metabolic one (trimetazidine). The treatment effect will be measured by the reduction of patients' angina symptoms, physical limitation and an improvement of quality of life using the Seattle Angina Questionnaire-7 items (SAQ-7) Patients will be also proposed to complete a BEAMER (BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe) questionnaire which will contribute to a separate research project developed by the Innovative Medicines Initiative (IMI). Analysis of the BEAMER questionnaires will be performed outside the study by the IMI BEAMER Consortium for BEAMER purposes only.
100 项与 SERVIER AFFAIRES MEDICALES 相关的临床结果
0 项与 SERVIER AFFAIRES MEDICALES 相关的专利（医药）
100 项与 SERVIER AFFAIRES MEDICALES 相关的药物交易
100 项与 SERVIER AFFAIRES MEDICALES 相关的转化医学
